Table 1.
Baseline characteristics of patients submitted to resection for hepatocellular carcinoma who did (Group A) and did not (Group B) survive for ≥10 years after resection (n = 176)
| Group A | Group B | ||
|---|---|---|---|
| Preoperative characteristics | (n = 28, 15.9%) | (n = 148, 84.1%) | P-value |
| Age, years, mean ± SD | 60.8 ± 12.1 | 57.5 ± 11.4 | 0.191 |
| Male gender, n (%) | 19 (67.9%) | 107 (72.3%) | 0.633 |
| Underlying liver disease, n (%) | 0.012 | ||
| Hepatitis B virus | 15 (53.6%) | 30 (20.3%) | |
| Hepatitis C virus | 9 (32.1%) | 59 (39.9%) | |
| Other | 1 (3.6%) | 23 (15.5%) | |
| None | 3 (10.7%) | 36 (24.3%) | |
| Stage 3–4 fibrosis, n (%) | 15 (53.6%) | 89 (60.1%) | 0.517 |
| Platelets <100 000/μl | 5 (21.0%) | 21 (15.2%) | 0.489 |
| (Missing data: 12, 6.8%) | |||
| AFP, mean ± SD | 7567 ± 33 070 | 6903 ± 60 350 | 0.926 |
| (Missing data: 28, 15.9%) | |||
| AFP of >400 ng/ml, n (%) | 7 (29.2%) | 40 (32.3%) | 0.766 |
| BCLC class at presentation, n (%) | 0.378 | ||
| (Missing data: 12, 6.8%) | |||
| A | 18 (66.7%) | 68 (48.9%) | |
| B | 3 (11.1%) | 26 (18.7%) | |
| C | 6 (22.2%) | 43 (30.9%) |
SD, standard deviation; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer.